NEXTCURE, INC Capital Expenditures
NEXTCURE, INC (NXTC) reported Capital Expenditures of $474.00 thousand for the 12-month period ending 2024-12-31, per its S-4 filed 2026-08-18.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-18
- NEXTCURE, INC payments to acquire property, plant, and equipment for the quarter ending 2024-12-31 was -$34.00K, a 361.54% decline year-over-year.
- NEXTCURE, INC payments to acquire property, plant, and equipment for the quarter ending 2024-09-30 was $170.00K, a 39.07% decline year-over-year.
- NEXTCURE, INC payments to acquire property, plant, and equipment for the quarter ending 2024-06-30 was $301.00K, a 7.50% increase year-over-year.
- NEXTCURE, INC payments to acquire property, plant, and equipment for the quarter ending 2024-03-31 was $37.00K, a 85.08% decline year-over-year.
- NEXTCURE, INC payments to acquire property, plant, and equipment for fiscal 2023 was $820.00K, a 61.25% decline from fiscal 2022.
- NEXTCURE, INC payments to acquire property, plant, and equipment for fiscal 2022 was $2.12M, a 10.34% decline from fiscal 2021.
- NEXTCURE, INC payments to acquire property, plant, and equipment for fiscal 2021 was $2.36M, a 66.91% decline from fiscal 2020.
- NEXTCURE, INC payments to acquire property, plant, and equipment for fiscal 2020 was $7.13M, a 111.57% increase from fiscal 2019.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$34.00K derived: S-4 12 month − 10-Q 9 month · filed 2026-08-18 | $136.00K derived: sum of 2 quarters · filed 2026-08-18 | $437.00K derived: sum of 3 quarters · filed 2026-08-18 | $474.00K S-4 · filed 2026-08-18 |
| 2024-09-30 | $170.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $471.00K derived: sum of 2 quarters · filed 2025-11-05 | $508.00K 10-Q · filed 2025-11-05 | $521.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $301.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $338.00K 10-Q · filed 2025-08-07 | $351.00K derived: sum of 3 quarters · filed 2025-08-07 | $630.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $37.00K 10-Q · filed 2025-05-01 | $50.00K derived: sum of 2 quarters · filed 2025-05-01 | $329.00K derived: sum of 3 quarters · filed 2025-05-01 | $609.00K derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $292.00K derived: sum of 2 quarters · filed 2025-03-06 | $572.00K derived: sum of 3 quarters · filed 2025-03-06 | $820.00K 10-K · filed 2025-03-06 |
| 2023-09-30 | $279.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $559.00K derived: sum of 2 quarters · filed 2024-11-07 | $807.00K 10-Q · filed 2024-11-07 | $1.67M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $280.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $528.00K 10-Q · filed 2024-08-01 | $1.39M derived: sum of 3 quarters · filed 2024-08-01 | $1.93M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $248.00K 10-Q · filed 2024-05-02 | $1.11M derived: sum of 2 quarters · filed 2024-05-02 | $1.65M derived: sum of 3 quarters · filed 2024-05-02 | $2.06M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $865.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $1.40M derived: sum of 2 quarters · filed 2024-03-21 | $1.81M derived: sum of 3 quarters · filed 2024-03-21 | $2.12M 10-K · filed 2024-03-21 |
| 2022-09-30 | $532.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $946.00K derived: sum of 2 quarters · filed 2023-11-02 | $1.25M 10-Q · filed 2023-11-02 | $2.08M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $414.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $719.00K 10-Q · filed 2023-08-03 | $1.54M derived: sum of 3 quarters · filed 2023-08-03 | $2.10M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $305.00K 10-Q · filed 2023-05-04 | $1.13M derived: sum of 2 quarters · filed 2023-05-04 | $1.69M derived: sum of 3 quarters · filed 2023-05-04 | $1.90M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $825.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $1.38M derived: sum of 2 quarters · filed 2023-03-02 | $1.59M derived: sum of 3 quarters · filed 2023-03-02 | $2.36M 10-K · filed 2023-03-02 |
| 2021-09-30 | $556.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $769.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.53M 10-Q · filed 2022-11-03 | $2.52M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $213.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $979.00K 10-Q · filed 2022-08-04 | $1.96M derived: sum of 3 quarters · filed 2022-08-04 | $3.83M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $766.00K 10-Q · filed 2022-05-05 | $1.75M derived: sum of 2 quarters · filed 2022-05-05 | $3.62M derived: sum of 3 quarters · filed 2022-05-05 | $6.45M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $980.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $2.85M derived: sum of 2 quarters · filed 2022-03-03 | $5.69M derived: sum of 3 quarters · filed 2022-03-03 | $7.13M 10-K · filed 2022-03-03 |
| 2020-09-30 | $1.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $4.71M derived: sum of 2 quarters · filed 2021-11-04 | $6.15M 10-Q · filed 2021-11-04 | $6.97M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $2.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $4.28M 10-Q · filed 2021-08-05 | $5.09M derived: sum of 3 quarters · filed 2021-08-05 | $5.58M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $1.45M 10-Q · filed 2021-05-06 | $2.26M derived: sum of 2 quarters · filed 2021-05-06 | $2.75M derived: sum of 3 quarters · filed 2021-05-06 | $3.88M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $814.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $1.30M derived: sum of 2 quarters · filed 2021-03-04 | $2.44M derived: sum of 3 quarters · filed 2021-03-04 | $3.37M 10-K · filed 2021-03-04 |
| 2019-09-30 | $490.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.62M derived: sum of 2 quarters · filed 2020-11-05 | $2.56M 10-Q · filed 2020-11-05 | $4.46M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $1.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $2.07M 10-Q · filed 2020-08-06 | $3.97M derived: sum of 3 quarters · filed 2020-08-06 | $4.28M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $935.00K 10-Q · filed 2020-05-07 | $2.84M derived: sum of 2 quarters · filed 2020-05-07 | $3.15M derived: sum of 3 quarters · filed 2020-05-07 | $3.53M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $2.21M derived: sum of 2 quarters · filed 2020-03-12 | $2.60M derived: sum of 3 quarters · filed 2020-03-12 | $3.06M 10-K · filed 2020-03-12 |
| 2018-09-30 | $306.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $694.00K derived: sum of 2 quarters · filed 2019-11-12 | $1.16M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $388.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $853.00K 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | $465.00K 10-Q · filed 2019-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |